Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Preeclampsia Screening Trial to Improve Outcomes (PRESTO)

10. listopadu 2026 aktualizováno: Suchitra Chandrasekaran, Emory University

Preeclampsia Screening Trial to Improve Outcomes: A Pre and Post Cohort Trial to Evaluate the Use of sFlt-1/PlGF Ratio in Women With Hypertensive Disorders of Pregnancy

The Pre-eclampsia Screening Trial to Improve Outcomes (PRESTO) research study aims to assess how clinicians use a blood test to guide care decisions in determining preeclampsia risk, with the overall aim of improving outcomes for both pregnant persons and their babies.

The study will evaluate whether a blood test can help doctors better identify pregnant patients with hypertensive disorders of pregnancy who are at risk of developing severe pre-eclampsia, which is a serious pregnancy condition that can affect organs such as the liver and kidneys and often leads to preterm delivery. The lab test measures two naturally occurring proteins in the blood that help estimate short-term risk for worsening disease. The goal is to determine whether providing this lab test result to clinicians can improve outcomes including safely prolong pregnancy, reduce unnecessary preterm deliveries, improve newborn outcomes, and optimize hospital care, without increasing complications for pregnant women or causing excess risks to the baby.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Participants will receive standard clinical care and will have a small blood sample drawn for the lab test. This study will have two phases: Phase A - the pre-phase and Phase B- the post-phase. The difference in the phases is whether test results are shared with doctors. Depending on when their hospital enters the study and which phase they are enrolled in, clinicians may or may not receive the test result, allowing researchers to compare outcomes before and after use of the test. Enrolled participants in both phases will have a blood draw, and data will be collected about their pregnancy and delivery.

Participants assigned to Phase A - the control phase, will not have their lab results shared with their doctor and will receive standard care. Participants assigned to Phase B - the intervention phase, will have their lab results shared with their doctor. Following phase A but before phase B, clinicians will receive education on the blood test and clinical management.

Participation lasts from hospital enrollment through delivery and discharge. Newborns will not undergo study procedures, but information will be collected from their medical records for them. The blood samples from the single lab draw will be stored temporarily for study analysis only and will not be banked for future unspecified research. No experimental drugs will be administered.

Typ studie

Intervenční

Zápis (Odhadovaný)

1000

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní místa

    • Georgia
      • Decatur, Georgia, Spojené státy, 30033
        • Emory Decatur Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Ženský

Popis

Inclusion Criteria:

  • Pregnant persons aged 18 years or older.
  • Singleton pregnancy.
  • Gestational age from 23 weeks 0 days through 33 weeks 6 days.
  • Presentation to obstetric triage or hospitalization for a hypertensive disorder of pregnancy.
  • Provision of signed informed consent (English- or Spanish-speaking).

Exclusion Criteria:

  • Enrollment in another therapeutic interventional trial with a primary outcome of HDP
  • Receipt of intravenous heparin during hospitalization.
  • Planned delivery upon admission for HDP within 48 hours of admission (If a patient is admitted with no immediate plan for delivery, but then a delivery decision is made, patients will still be included and analyzed accordingly)
  • Prior study enrollment during the current pregnancy.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Diagnostický
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: Blinded Test Results (Phase A)

Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units.

Triage units will be considered part of Labor & Delivery for this study. Management proceeds per local standard of care.

Blood samples for sFlt-1/PlGF measurement will be collected and stored for later analysis; however, test results will remain blinded to clinicians and will not be available to guide clinical management during this phase. Biomarker measurements will be analyzed retrospectively for research purposes.

Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

Ostatní jména:
  • Plasma sFlt-1/PlGF biomarker
  • Preclara
Experimentální: Real Time Results (Phase B)

Patients will be enrolled upon admission to the Labor & Delivery/Maternity or antepartum units. Triage units will be considered part of Labor & Delivery for this study.

During the Intervention phase (post-implementation), results are reported in real time (within 24 hours) to treating clinicians. Management proceeds per the treating clinician, who has been educated to use the FDA-approved algorithm for the use of the test.

Serum sFlt-1/PlGF biomarker, authorized by the U.S. Food and Drug Administration for use in pregnant patients with hypertensive disorders of pregnancy from 23+0 through 33+6 weeks of gestation.

Ostatní jména:
  • Plasma sFlt-1/PlGF biomarker
  • Preclara

sFlt-1/PlGF measurements will be available to clinicians in real time and may be incorporated into clinical management according to the FDA-approved algorithm

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Pregnancy latency
Časové okno: At delivery (up to 40 weeks of gestation)

Time from admission to delivery

At delivery (up to 40 weeks of gestation)
Participants with maternal adverse outcomes
Časové okno: From enrollment until post-natal discharge (on average 10 days post-delivery)

The number of participants who experience one or more of the following maternal adverse events: cerebral hemorrhage, seizures (eclampsia), pulmonary edema, disseminated intravascular coagulation (DIC), new onset acute renal failure (creatinine > 1.4), peripartum cardiomyopathy, ischemic stroke, or HELLP syndrome [doubling of liver function test (LFT) and platelets count<100,000] or severe hypertension that required a parenteral infusion of a third-line antihypertensive.

From enrollment until post-natal discharge (on average 10 days post-delivery)

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Number of participants who require hospital admission
Časové okno: From enrollment up to 37 weeks of gestation

Number of participants who require hospital admission during study participation, collected form medical records.

From enrollment up to 37 weeks of gestation
Number of participants with indicated delivery within 14 days of presentation
Časové okno: Up to 14 days from enrollment

Participants who require delivery within 14 days of presentation

Up to 14 days from enrollment
Number of participants who require transfer to tertiary care centers
Časové okno: From enrollment until post-natal hospital discharge (on average 10 days post-delivery)

Participants who require transfer to tertiary care centers as documented in the medical records.

From enrollment until post-natal hospital discharge (on average 10 days post-delivery)
Number of participants who received antenatal corticosteroid administration
Časové okno: Between 24 weeks and 34 weeks of gestation

Participants who receive antenatal corticosteroid administration as documented in the medical records.

Between 24 weeks and 34 weeks of gestation
Number of preterm births less than 37 weeks
Časové okno: From enrollment up to 36 weeks and 6 days of pregnancy

Preterm births at <37 weeks' gestation between the pre-implementation and post-implementation periods.

From enrollment up to 36 weeks and 6 days of pregnancy
Number of early preterm births
Časové okno: From enrollment up to 31 weeks and 6 days of pregnancy

Early preterm births at <32 weeks' gestation between the pre-implementation and post-implementation periods. Analyses of preterm birth <32 weeks will be restricted to individuals enrolled before 32 weeks' gestation.

From enrollment up to 31 weeks and 6 days of pregnancy
Composite Adverse Fetal/Neonatal Outcomes
Časové okno: From maternal enrollment through 28 days after birth

Composite outcome defined as the occurrence of one or more of the following fetal or neonatal adverse events: fetal or neonatal death, low birth weight (<2500 g), respiratory distress syndrome (RDS), bronchopulmonary dysplasia, retinopathy of prematurity, necrotizing enterocolitis, or grade III/IV intraventricular hemorrhage. The proportion of participants experiencing the composite outcome will be compared between the intervention and control groups.

From maternal enrollment through 28 days after birth
Length of hospital admission (mother's) of stay,
Časové okno: From admission until post-natal hospital discharge (on average 10 days post-delivery)

Length of hospital admission, extracted from medical records

From admission until post-natal hospital discharge (on average 10 days post-delivery)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Suchitra Chandrasekaran, MD, Emory University

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. prosince 2026

Primární dokončení (Odhadovaný)

1. června 2028

Dokončení studie (Odhadovaný)

1. června 2028

Termíny zápisu do studia

První předloženo

14. října 2026

První předloženo, které splnilo kritéria kontroly kvality

10. listopadu 2026

První zveřejněno (Aktuální)

16. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

16. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

10. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • 2026P000788

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

Individual de-identified participant data may be made available upon reasonable request, subject to Sponsor review.

The specific data to be shared will be determined based on the Sponsor's review of the requested data and the nature of the request.

Časový rámec sdílení IPD

No specific end date has been established.

Kritéria přístupu pro sdílení IPD

Requests will be reviewed by the Research Team, and approved data will be shared through a method determined Requests will be reviewed by the Sponsor, and approved data will be shared through an appropriate method determined at the time of approval. Data will be shared with the Qualified researchers or organizations whose requests are approved by the Sponsor. Contingent upon the Sponsor's approved data request.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ano

produkt vyrobený a vyvážený z USA

Ano

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .